Finance

Lists
603087:SHA
Gan & Lee Pharmaceuticals
CNÂ¥63.51
-0.92%
(-0.59) 1D
Nov 17, 3:00:01 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603087...
Open
CNÂ¥63.78
High
CNÂ¥64.65
Low
CNÂ¥63.13
Mkt. cap
38.30B
Avg. vol.
7.64M
Volume
4.41M
Dividend
1.57%
Quarterly dividend
CNÂ¥0.25
Ex-dividend date
May 29, 2026
P/E ratio
31.84
52-wk high
CNÂ¥79.99
52-wk low
CNÂ¥51.51
EPS
CNÂ¥1.99
No. of employees
5K
Open
CNÂ¥63.78
High
CNÂ¥64.65
Low
CNÂ¥63.13
Mkt. cap
38.30B
Avg. vol.
7.64M
Volume
4.41M
Dividend
1.57%
Quarterly dividend
CNÂ¥0.25
Ex-dividend date
May 29, 2026
P/E ratio
31.84
52-wk high
CNÂ¥79.99
52-wk low
CNÂ¥51.51
EPS
CNÂ¥1.99
No. of employees
5K
News stories
From web sources and news partners
About Gan & Lee Pharmaceuticals
CEO-
Employees5.31K
FoundedJun 17, 1998
Headquarters-
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.01B
878.11M
1.34B
1.15B
Cost of goods sold
259.72M
223.40M
359.10M
264.14M
Cost of revenue
259.72M
223.40M
359.10M
264.14M
Research and development expenses
239.11M
128.04M
170.06M
164.93M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
444.21M
327.25M
377.07M
427.40M
Operating expense
709.00M
462.53M
557.24M
594.93M
Total operating expenses
968.72M
685.94M
916.35M
859.07M
Operating income
36.39M
192.17M
428.57M
286.95M
Other non operating income
-70.56M
-1.12M
3.22M
-8.92M
EBT including unusual items
304.10M
212.64M
474.46M
289.06M
EBT excluding unusual items
257.75M
205.87M
465.75M
282.84M
Income tax expense
-21.15M
20.18M
57.59M
40.76M
Effective tax rate
-6.95%
9.49%
12.14%
14.10%
Other operating expenses
25.46M
7.75M
9.04M
5.40M
Net income
325.24M
192.49M
417.29M
248.30M
Net profit margin
32.36%
21.92%
31.03%
21.67%
Earnings per share
-
-
-
-
Interest and investment income
303.56M
14.82M
55.17M
102.21K
Interest expense
-231.14K
-
-102.21K
-16.40M
Net interest expenses
303.33M
14.82M
55.07M
-16.30M
Depreciation and amortization charges
-
-
-
-
EBITDA
110.65M
266.44M
519.60M
361.22M
Gain or loss from assets sale
-3.71M
-
54.15K
-54.15K
Upcoming events
AI content may include mistakes. Learn more
Google apps